Other hallucinogen use disorder

WikiDoc Resources for Other hallucinogen use disorder
Articles
Most recent articles on Other hallucinogen use disorder Most cited articles on Other hallucinogen use disorder Review articles on Other hallucinogen use disorder Articles on Other hallucinogen use disorder in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Other hallucinogen use disorder Images of Other hallucinogen use disorder Photos of Other hallucinogen use disorder Podcasts & MP3s on Other hallucinogen use disorder Videos on Other hallucinogen use disorder
Evidence Based Medicine
Cochrane Collaboration on Other hallucinogen use disorder Bandolier on Other hallucinogen use disorder TRIP on Other hallucinogen use disorder
Clinical Trials
Ongoing Trials on Other hallucinogen use disorder at Clinical Trials.gov Trial results on Other hallucinogen use disorder Clinical Trials on Other hallucinogen use disorder at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Other hallucinogen use disorder NICE Guidance on Other hallucinogen use disorder NHS PRODIGY Guidance FDA on Other hallucinogen use disorder CDC on Other hallucinogen use disorder
Books
Books on Other hallucinogen use disorder
News
Other hallucinogen use disorder in the news Be alerted to news on Other hallucinogen use disorder News trends on Other hallucinogen use disorder
Commentary
Blogs on Other hallucinogen use disorder
Definitions
Definitions of Other hallucinogen use disorder
Patient Resources / Community
Patient resources on Other hallucinogen use disorder Discussion groups on Other hallucinogen use disorder Patient Handouts on Other hallucinogen use disorder Directions to Hospitals Treating Other hallucinogen use disorder Risk calculators and risk factors for Other hallucinogen use disorder
Healthcare Provider Resources
Symptoms of Other hallucinogen use disorder Causes & Risk Factors for Other hallucinogen use disorder Diagnostic studies for Other hallucinogen use disorder Treatment of Other hallucinogen use disorder
Continuing Medical Education (CME)
CME Programs on Other hallucinogen use disorder
International
Other hallucinogen use disorder en Espanol Other hallucinogen use disorder en Francais
Business
Other hallucinogen use disorder in the Marketplace Patents on Other hallucinogen use disorder
Experimental / Informatics
List of terms related to Other hallucinogen use disorder

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2] Synonyms and keywords:

Differential Diagnosis

• Alcohol withdrawal
• Bipolar disorders
• Central nervous system tumors
• Depressive disorder
• Hypoglycemia
• Panic disorder
• Schizophrenia
• Sedative withdrawal
• Seizure disorder
• Stroke
• Ophthalmological disorder
• Other substance use disorders

Risk Factors

• Alcohol intake
• Tobacco usage
• Cannabis usage
• Major depressive disorder

Epidemiology and Demographics

Prevalence

The 12-month prevalence is 500 per 100,000 (0.5%) among 12- to 17-year-olds and 100 per 100,000 (0.1%) among adults age 18 and older in the United States.

Risk Factors

• Younger age than 30-year-old
• Female gender

Natural History, Complications and Prognosis

Prognosis

Poor prognostic factors includes:

• Increasing in dose intake
• Impairment in daily activities

Diagnostic Criteria

DSM-V Diagnostic Criteria for Other Hallucinogen Use Disorder

“

A. A problematic pattern of hallucinogen (other than phencyclidine) use leading to clinically significant impairment or distress, as manifested by at least two of the following, occurring within a 12-month period: The hallucinogen is often taken in larger amounts or over a longer period than was intended. There is a persistent desire or unsuccessful efforts to cut down or control hallucinogen use. A great deal of time is spent in activities necessary to obtain the hallucinogen, use the hallucinogen, or recover from its effects. Craving, or a strong desire or urge to use the hallucinogen. Recurrent hallucinogen use resulting in a failure to fulfill major role obligations at work, school, or home (e.g., repeated absences from work or poor work performance related to hallucinogen use; hallucinogen-related absences, suspensions, or expulsions from school; neglect of children or household). Continued hallucinogen use despite having persistent or recurrent social or inter personal problems caused or exacerbated by the effects of the hallucinogen (e.g., arguments with a spouse about consequences of intoxication; physical fights). Important social, occupational, or recreational activities are given up or reduced be cause of hallucinogen use. Recurrent hallucinogen use in situations in which it is physically hazardous (e.g., driving an automobile or operating a machine when impaired by the hallucinogen). hallucinogen use is continued despite knowledge of having a persistent or recur rent physical or psychological problem that is likely to have been caused or exacerbated by the hallucinogen. Tolerance, as defined by either of the following: A need for markedly increased amounts of the hallucinogen to achieve intoxication or desired effect. A markedly diminished effect with continued use of the same amount of the hallucinogen. Note: Withdrawal symptoms and signs are not established for hallucinogens, and so this criterion does not apply. Specify the particular hallucinogen. Specify if: In early remission: After full criteria for other hallucinogen use disorder were previously met, none of the criteria for other hallucinogen use disorder have been met for at least 3 months but for less than 12 months (with the exception that Criterion A4, “Craving, or a strong desire or urge to use the hallucinogen,” may be met). In sustained remission: After full criteria for other hallucinogen use disorder were previously met, none of the criteria for other hallucinogen use disorder have been met at any time during a period of 12 months or longer (with the exception that Criterion A4, “Craving, or a strong desire or urge to use the hallucinogen,” may be met). Specify if: In a controlled environment: This additional specifier is used if the individual is in an environment where access to hallucinogens is restricted. Specify current severity: Mild: Presence of 2-3 symptoms. Moderate: Presence of 4-5 symptoms. Severe: Presence of 6 or more symptoms.

”